NASDAQ:IMRA

IMARA Competitors

$7.29
-0.38 (-4.95 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.26
Now: $7.29
$7.64
50-Day Range
$7.67
MA: $10.05
$13.86
52-Week Range
$7.26
Now: $7.29
$62.71
Volume107,155 shs
Average Volume158,507 shs
Market Capitalization$128.12 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

IMARA (NASDAQ:IMRA) Vs. MRNS, RAPT, AKUS, AMYT, AVDL, and XBIT

Should you be buying IMRA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IMARA, including Marinus Pharmaceuticals (MRNS), RAPT Therapeutics (RAPT), Akouos (AKUS), Amryt Pharma (AMYT), Avadel Pharmaceuticals (AVDL), and XBiotech (XBIT).

Marinus Pharmaceuticals (NASDAQ:MRNS) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

79.3% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. 2.8% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Marinus Pharmaceuticals and IMARA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marinus PharmaceuticalsN/AN/A$-54,120,000.00($3.96)-3.53
IMARAN/AN/AN/AN/AN/A

Profitability

This table compares Marinus Pharmaceuticals and IMARA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Marinus PharmaceuticalsN/A-95.56%-66.01%
IMARAN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Marinus Pharmaceuticals and IMARA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Marinus Pharmaceuticals00903.00
IMARA00303.00

Marinus Pharmaceuticals currently has a consensus price target of $28.75, indicating a potential upside of 105.50%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's higher possible upside, analysts plainly believe IMARA is more favorable than Marinus Pharmaceuticals.

RAPT Therapeutics (NASDAQ:RAPT) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares RAPT Therapeutics and IMARA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-2.05
IMARAN/AN/AN/AN/AN/A

Profitability

This table compares RAPT Therapeutics and IMARA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
IMARAN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for RAPT Therapeutics and IMARA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00503.00
IMARA00303.00

RAPT Therapeutics currently has a consensus price target of $41.20, indicating a potential upside of 103.06%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's higher possible upside, analysts plainly believe IMARA is more favorable than RAPT Therapeutics.

Akouos (NASDAQ:AKUS) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

88.7% of Akouos shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Akouos and IMARA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
IMARAN/AN/AN/AN/AN/A

Profitability

This table compares Akouos and IMARA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
IMARAN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Akouos and IMARA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos01302.75
IMARA00303.00

Akouos currently has a consensus price target of $31.6667, indicating a potential upside of 118.24%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's stronger consensus rating and higher possible upside, analysts plainly believe IMARA is more favorable than Akouos.

Summary

IMARA beats Akouos on 2 of the 3 factors compared between the two stocks.

Amryt Pharma (NASDAQ:AMYT) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Amryt Pharma and IMARA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amryt PharmaN/AN/AN/A
IMARAN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Amryt Pharma and IMARA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amryt Pharma01302.75
IMARA00303.00

Amryt Pharma currently has a consensus price target of $38.00, indicating a potential upside of 174.37%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's stronger consensus rating and higher possible upside, analysts plainly believe IMARA is more favorable than Amryt Pharma.

Valuation and Earnings

This table compares Amryt Pharma and IMARA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma$58.12 million8.55$-30,854,220.00($0.86)-16.11
IMARAN/AN/AN/AN/AN/A

IMARA has lower revenue, but higher earnings than Amryt Pharma.

Institutional and Insider Ownership

15.4% of Amryt Pharma shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

IMARA beats Amryt Pharma on 3 of the 4 factors compared between the two stocks.

IMARA (NASDAQ:IMRA) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares IMARA and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMARAN/AN/AN/A
Avadel Pharmaceuticals38.70%-33.91%-11.75%

Analyst Ratings

This is a summary of recent ratings for IMARA and Avadel Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMARA00303.00
Avadel Pharmaceuticals00603.00

IMARA presently has a consensus price target of $35.3333, suggesting a potential upside of 384.68%. Avadel Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 120.38%. Given IMARA's higher possible upside, equities analysts clearly believe IMARA is more favorable than Avadel Pharmaceuticals.

Valuation & Earnings

This table compares IMARA and Avadel Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMARAN/AN/AN/AN/AN/A
Avadel Pharmaceuticals$59.22 million8.33$-33,230,000.00($0.89)-9.48

IMARA has higher earnings, but lower revenue than Avadel Pharmaceuticals.

Institutional & Insider Ownership

64.5% of IMARA shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

IMARA (NASDAQ:IMRA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares IMARA and XBiotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMARAN/AN/AN/A
XBiotechN/A-7.07%-6.67%

Analyst Ratings

This is a summary of recent ratings for IMARA and XBiotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMARA00303.00
XBiotech0000N/A

IMARA presently has a consensus price target of $35.3333, suggesting a potential upside of 384.68%. Given IMARA's higher possible upside, equities analysts clearly believe IMARA is more favorable than XBiotech.

Valuation & Earnings

This table compares IMARA and XBiotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMARAN/AN/AN/AN/AN/A
XBiotechN/AN/A$668.63 millionN/AN/A

Institutional & Insider Ownership

64.5% of IMARA shares are held by institutional investors. Comparatively, 14.8% of XBiotech shares are held by institutional investors. 31.0% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

IMARA beats XBiotech on 5 of the 6 factors compared between the two stocks.


IMARA Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.99-10.9%$511.73 millionN/A-4.03News Coverage
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.29-3.7%$504.53 millionN/A-7.99News Coverage
Akouos logo
AKUS
Akouos
1.6$14.51-4.4%$499.17 millionN/A0.00
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.86-1.0%$497.08 million$58.12 million-16.11
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.44-4.0%$493.45 million$59.22 million42.20
XBiotech logo
XBIT
XBiotech
1.0$16.75-1.2%$493.44 millionN/A1.16
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.38-1.8%$485.50 millionN/A-2.55
AC Immune logo
ACIU
AC Immune
1.3$6.62-3.8%$476.22 million$111.75 million-7.36
89bio logo
ETNB
89bio
1.6$23.80-10.4%$474.72 millionN/A-4.71
Altimmune logo
ALT
Altimmune
1.9$12.57-2.6%$466.98 million$5.80 million-6.32
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.91-17.0%$458.09 million$40,000.00-1.47High Trading Volume
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.98-2.7%$457.44 million$335 million-1.01
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.48-2.7%$454.38 million$56.50 million0.00Analyst Downgrade
Geron logo
GERN
Geron
1.4$1.42-4.2%$452.31 million$460,000.00-4.06
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.94-4.4%$451.96 million$109.33 million-2.16Analyst Report
News Coverage
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.14-1.2%$446.96 millionN/A0.00
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.29-0.9%$445.41 million$102.31 million6.40
Verastem logo
VSTM
Verastem
1.3$2.57-7.4%$441.18 million$17.46 million-1.82Analyst Revision
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.75-1.4%$439.95 millionN/A0.00Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.82-5.2%$438.33 million$22.27 million-3.83Insider Buying
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$6.74-14.5%$436.64 million$57.49 million-5.66
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.86-1.0%$434.05 millionN/A-11.95News Coverage
XOMA logo
XOMA
XOMA
1.3$37.98-2.7%$427.39 million$18.37 million-34.22
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.80-10.0%$427.02 million$6.68 million-4.58
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.31-2.7%$424.21 millionN/A-3.43
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$6.87-10.2%$422.86 million$6.07 million-3.29
BCEL
Atreca
1.7$11.48-7.1%$422.82 millionN/A-4.07Gap Down
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$8.31-2.3%$414.87 million$72.96 million-2.69News Coverage
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.26-3.6%$411.77 million$380,000.000.00Analyst Downgrade
BeyondSpring logo
BYSI
BeyondSpring
1.2$10.24-0.5%$400.81 millionN/A-5.02
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$32.39-1.6%$400.50 million$206.55 million-16.28
DURECT logo
DRRX
DURECT
1.4$1.74-6.3%$395.33 million$29.56 million-34.79
Sesen Bio logo
SESN
Sesen Bio
1.2$2.32-8.6%$392.98 millionN/A-5.27Gap Up
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.36-2.7%$392.02 million$1.98 million-3.83
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.56-6.4%$390.39 million$9.48 million-0.26
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
0.9$19.64-0.5%$388.79 million$362.21 million23.66
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.62-3.0%$387.28 million$272.30 million-6.73
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.22-3.2%$385.46 million$16.54 million-3.34High Trading Volume
Unusual Options Activity
News Coverage
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$12.96-0.9%$382.37 million$18.15 million-3.05News Coverage
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.39-1.5%$381.47 million$28.91 million-5.65
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.51-3.1%$376.06 millionN/A-4.00Analyst Report
News Coverage
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$16.13-3.4%$375.86 millionN/A0.00Lockup Expiration
Athenex logo
ATNX
Athenex
1.6$4.02-2.0%$375.69 million$101.23 million-2.75
Athersys logo
ATHX
Athersys
1.3$1.74-2.3%$374.53 million$5.63 million-4.70
Theratechnologies logo
THTX
Theratechnologies
1.1$3.96-3.5%$371.61 million$63.22 million-12.77Upcoming Earnings
News Coverage
UroGen Pharma logo
URGN
UroGen Pharma
1.8$17.57-9.3%$367.16 million$20,000.00-2.75
Homology Medicines logo
FIXX
Homology Medicines
1.6$7.17-2.1%$362.00 million$1.67 million-2.63High Trading Volume
BELLUS Health logo
BLU
BELLUS Health
1.7$4.54-3.5%$355.65 million$30,000.00-7.69
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.09-8.3%$353.07 millionN/A-0.31Analyst Revision
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.50-1.4%$353.02 million$111.39 million25.00News Coverage
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.